Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Depreciation & Amortization (CF) (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $323000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 14.1% to $323000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 6.27% year-over-year, with the annual reading at $1.5 million for FY2025, 6.27% down from the prior year.
  • Depreciation & Amortization (CF) hit $323000.0 in Q4 2025 for Xilio Therapeutics, down from $340000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $497000.0 in Q1 2025 to a low of $323000.0 in Q4 2025.